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SUMMARY
A clinical trial with a 2 × 2 factorial design involves randomization of subjects to treatment A or 
and, within each group, further randomization to treatment B or . Under this design, one can 
assess the effects of treatments A and B on a clinical endpoint using all patients. One may 
additionally compare treatment A, treatment B, or combination therapy AB to . With multiple 
comparisons, however, it may be desirable to control the overall type I error, especially for 
regulatory purposes. Because the subjects overlap in the comparisons, the test statistics are 
generally correlated. By accounting for the correlations, one can achieve higher statistical power 
compared to the conventional Bonferroni correction. Herein, we derive the correlation between 
any two (stratified or unstratified) log-rank statistics for a 2 × 2 factorial design with a survival 
time endpoint, such that the overall type I error for multiple treatment comparisons can be 
properly controlled. In addition, we allow for adjustment of prognostic factors in the treatment 
comparisons and conduct simultaneous inference on the effect sizes. We use simulation studies to 
show that the proposed methods perform well in realistic situations. We then provide an 
application to a recently completed randomized controlled clinical trial on alcohol dependence. 
Finally, we discuss extensions of our approach to other factorial designs and multiple endpoints.
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1. Introduction
Factorial designs are commonly used in clinical trials to evaluate the effects of multiple 
treatments on potentially censored survival time or times to other clinical events. For 
example, the Physicians’ Health Study adopted a 2 × 2 factorial design to investigate the 
effects of aspirin and beta-carotene on cardiovascular mortality and incidence of cancer 
among 22,000 male physicians aged 40–84 years (Stampfer et al., 1985). As a second 
example, the Women’s Health Initiative employed a partial factorial design to study the 
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effectiveness of dietary modification, hormone therapy, and calcium/vitamin D 
supplementation in preventing coronary heart disease, breast and colorectal cancer, and hip 
fracture among 68,132 postmenopausal women (Prentice and Anderson, 2007). Recently, we 
were involved in two clinical trials with factorial designs:
The COMBINE Study
The Combined Pharmacotherapies and Behavioral Interventions (COMBINE) study was 
conducted between January 2001 and January 2004 to evaluate the efficacy of medication, 
behavioral therapy, and their combination for treatment of alcohol dependence among 1,224 
recently alcohol-abstinent volunteers (Anton et al., 2006). Patients were randomized to 
receive medical management with 16 weeks of naltrexone (100 mg daily) or placebo, with or 
without a combined behavioral intervention (CBI) under a factorial design; see Table 1. The 
investigators were interested in assessing the effects of each intervention as a mono-therapy, 
as well as the combined effect of the two interventions, on time to the first day of heavy 
drinking and other endpoints.
The APOLLO Trial
The Aliskiren Prevention of Later Life Outcomes (APOLLO) trial was designed to 
investigate the impact of aliskiren, alone or in combination with other drugs, on clinical 
outcomes in elderly patients with hypertension (Teo et al., 2014). Participants were 
randomized to aliskiren 300 mg daily or placebo and also to an additional antihypertensive 
drug (amlodipine 5 mg daily or HCTZ 25 mg daily) or placebo under a factorial design; see 
Table 2. There were two primary objectives in this study: one was to determine whether 
treatment with an aliskiren-based regimen reduces the risk of major cardiovascular events 
(i.e., death, myocardial infarction, stroke, and significant heart failure) when compared to a 
non-aliskiren based regimen; and the second was to determine whether intensified therapy 
with aliskiren plus an additional antihypertensive drug will reduce the risk of major 
cardiovascular events when compared to double placebo. The planned sample size was 
11,000, with 2,750 patients for each of the four treatment combinations, but the trial was 
terminated for non-scientific reasons after enrollment of 1,759 patients (Teo et al., 2014).
In the Physicians’ Health Study, the primary hypothesis pertains to the effect of aspirin on 
cardiovascular mortality and the secondary hypothesis pertains to the effect of beta-carotene 
on incidence of cancer. These are two distinct scientific questions. Likewise, the three 
questions considered in the Women’s Health Initiative are scientifically distinct. There is no 
need to adjust for multiple testing in such studies (Cook and Farewell, 1996).
In the COMBINE and APOLLO studies, the same set of subjects is used to assess the effects 
of interventions with similar mechanisms or purposes on the same endpoint. In such cases, it 
may be necessary to adjust for multiple comparisons, especially when they allow different 
ways to make a positive claim for the benefit of an investigational treatment. Since the 
subjects overlap in the comparisons, the test statistics are generally dependent. By 
accounting for this dependence, we can achieve higher statistical power compared to the 
conventional Bonferroni correction. For the survival endpoint, each treatment comparison is 
carried out by a (stratified or unstratified) log-rank test. Because log-rank statistics are not 
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sums of independent random variables, it is not straightforward to determine the correlation 
of two log-rank statistics with overlapping subjects.
Although there is some statistical literature on 2 × 2 factorial survival experiments, no 
methods are available to calculate the correlations of the log-rank statistics for the types of 
comparisons performed in the COMBINE and APOLLO studies. The most relevant work is 
that of Slud (1994), who adopted the proportional hazards (PH) model (Cox, 1972) with two 
treatment indicators and their product as independent variables. Akritas and LaValley (1996) 
considered the accelerated failure time model (Kalbfleisch and Prentice, 2002, p. 44) instead 
of the PH model and proposed an extension of the Hodges-Lehmann estimator. Akritas and 
Brunner (1997) constructed nonparametric tests based on the Kaplan-Meier estimators for 
the four treatment combinations.
In this paper, we derive the correlation between any two (stratified or unstratified) log-rank 
statistics under the 2 × 2 factorial design, such that the overall type I error of multiple 
treatment comparisons can be properly controlled. Actually, our work goes beyond this 
derivation by allowing for adjustment of prognostic factors and by performing simultaneous 
estimation in addition to simultaneous testing. We assess the accuracy of the proposed 
correlation formulas in simulation studies. In addition, we apply the proposed methods to 
data derived from the COMBINE study. Finally, we discuss extensions of our approach to 
other factorial designs and multiple endpoints.
2. Methods
Consider the 2 × 2 factorial design, and let A and B denote the two treatments. Subjects are 
randomly assigned to A or  and B or  such that there are four possible treatment arms, as 
shown in the following table:
AB
A major advantage of this design is that one can assess the effects of treatments A and B on 
survival time using all subjects. That is, one can assess the overall effect of treatment A by 
comparing the two columns in the above table or the overall effect of treatment B by 
comparing the two rows. One may additionally evaluate the simple effect of combination 
therapy AB (i.e., the comparison of the two cells on the main diagonal) or the simple effects 
of A and B (i.e.,  versus  and  versus ). Note that we use the term “overall 
effect” to refer to the effect of one intervention on survival time across the levels of the other 
intervention and the term “simple effect” to refer to the effect of one or two interventions on 
survival time compared to double placebo or standard care.
To test the null hypothesis that the overall effect of treatment A is zero, it is natural to 
employ the stratified log-rank statistic by stratifying subjects as to whether they receive 
treatment B or not (Peto, 1978). The stratified log-rank statistic compares A and  among 
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subjects who receive B and separately among those who receive  and then combines the 
evidence from the two strata. By contrast, the unstratified log-rank statistic compares all 
subjects who receive A with all subjects who receive  regardless of whether they receive B 
or . To test the null hypothesis that a simple effect is zero, we employ the unstratified log-
rank statistic (since we are comparing two cells only). To quantify the treatment effect or to 
adjust for covariates, we appeal to the (stratified or unstratified) PH model. It is sufficient to 
focus on the PH model because the log-rank statistic is the score statistic under the PH 
model with the treatment indicator as the only independent variable. Our main task is to 
derive the joint distribution of the score statistics and the corresponding parameter 
estimators under two (possibly stratified) PH models with overlapping subjects.
Since the unstratified PH model is a special case of the stratified PH model with a single 
stratum, it suffices to consider the stratified PH model. Suppose that, for the first treatment 
comparison, there are K strata with nk subjects in the kth stratum. In our case, K = 1 (for 
unstratified analysis) or 2 (for stratified analysis). For k = 1, …, K and j = 1, …, nk, let Tkj 
denote the survival time for the jth subject of the kth stratum, and let Xkj denote the 
corresponding set of independent variables, including the treatment indicator (e.g., indicator 
of A versus  or indicator of AB versus ) and baseline covariates (e.g., age, gender, and 
clinical center). The stratified PH model takes the form
(1)
where β is a set of regression parameters pertaining to log hazard ratios, and λk0(·) (k = 1, 
…, K) are arbitrary baseline hazard functions.
For assessing the overall effect of A, it is desirable to stratify on B (Peto, 1978). Under the 
stratified PH model, the effects of A are assumed to be the same for subjects receiving B and 
for those receiving  while the difference between B and  is completely unspecified. 
Although the assumption of a common effect of A between the two strata may not hold 
(under alternatives), the stratified model is well defined and does not depend on the 
proportion of subjects receiving B (as opposed to ). (It is possible to allow the effects of A 
to be different between the two strata, but then one would effectively be fitting two separate 
models.) Under the unstratified PH model, the baseline hazard function is a mixture of the 
hazard functions for  and , and thus its value depends on the proportion of subjects 
receiving B. Indeed, if the proportion of subjects receiving B is random (due to sampling or 
noncompliance), then the baseline hazard function and the regression effects are random 
quantities.
Let Ckj denote the censoring time for Tkj such that we observe  and Δkj 
≡ I(Tkj ≤ Ckj), where I (·) is the indicator function. Define
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where a⊗0 = 1, a⊗1 = a, and a⊗2 = aaT. We estimate β by maximizing the partial likelihood 
function
The corresponding score function is
and the corresponding information matrix is
Denote the maximum partial likelihood estimator of β by . For large samples,  is 
multivariate normal with mean β and covariance matrix  (Andersen and Gill, 1982).
For the second treatment comparison, we consider the following stratified PH model
(2)
where  pertains to the treatment indicator for this comparison and baseline covariates, γ 
is a set of regression parameters, and  are arbitrary baseline hazard 
functions. Estimation of model (2) proceeds in the same manner as that of model (1). Let 
denote the maximum partial likelihood estimator of γ, and let  and  denote the 
score function and information matrix, respectively.
To derive the joint distribution between  and , we approximate U(β) and  by sums of 
independent terms. Specifically, U(β) is approximated by  where wkj(β) 
is a random vector that involves only the data on the jth subject of the kth stratum; see 
equation (A.2) in the Appendix. Likewise, . Replacing the 
unknown quantities in wkj(β) by their sample estimators yields
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Likewise, we obtain the empirical counterpart of , denoted by . Let n0 be the 
number of subjects that are used in fitting both models (1) and (2). For i = 1, …, n0, let 
Wi(β) be the value of Wkj(β) for the ith subject, and let  be the value of  for 
the same subject. For large samples, the joint distribution of  and  is approximately 
multivariate normal, and the covariance matrix between  and  can be estimated by 
, where  is the estimated 
covariance matrix between U(β) and .
Remark 1
If one is only interested in simple effects with a common set of covariates, then one can fit a 
single (unstratified) PH model with appropriate treatment indicators and obtain the 
covariance matrix of the estimated effects from standard statistical software.
The above results allow us to make joint inference on β and γ. Without loss of generality, 
assume that the first components of β and γ, denoted by β1 and γ1, respectively, correspond 
to the treatment effects. Let  and  denote the maximum partial likelihood estimators of 
β1 and γ1, and let  denote the (estimated) covariance matrix of 
. To test jointly the null hypotheses H0 : β1 =0 and  we can use the 
quadratic form, , which is referred to the chi-squared distribution 
with 2 degrees of freedom. The values of β1 and γ1 such that 
 form a joint (1 − α) confidence region 
for β1 and γ1, where  is the (1 − α) 100th percentile of the chi-squared distribution with 
2 degrees of freedom.
Define  and  A multiple testing procedure with an overall type I error 
of α is to reject H0 if |Z| ≥ c and reject  if , where c satisfies the equation
(4)
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We evaluate this probability through multivariate normal integration, treating  as 
bivariate zero-mean normal with unit variances and covariance . The 
confidence intervals for β1 and γ1 based on c have the joint coverage probability of (1 − α).
Remark 2
We have implicitly assumed that the overall type I error is split equally between the two 
comparisons. One may spend more type I error on one hypothesis than the other by using 
different critical values for Z and  as long as the overall rejection probability satisfies 
equation (4).
Remark 3
We have assumed that the primary analysis involves two treatment comparisons. However, 
the aforementioned joint inference procedures can be easily extended to three or more 
comparisons since the correlation matrix is determined by the pairwise correlations.
We now consider the special case of treatment comparisons without covariate adjustment. 
For the first comparison, we use the stratified (weighted) log-rank statistic
where  and Qk(·) is a possibly data-
dependent weight function. The variance of U is estimated by
Let and  be the values of U and V, respectively, for the second comparison. For the 
unweighted log-rank statistics (i.e., Qk(·) = 1), U = U(0) and , such that the 
covariance between U and  can be estimated by R(0, 0). For non-constant weight 
functions, we replace Δkj and Δkl in (3) by  and , respectively, 
before evaluating R(0, 0). Let Z = U/V1/2 and . Under H0 and ,  is 
approximately bivariate zero-mean normal with unit variances and covariance 
. This bivariate normal distribution can be used to determine the critical 
value c in equation (4).
It is desirable to determine the critical value c analytically, especially in the design stage. 
Suppose that the treatments do not affect the survival time or censoring time and that the 
treatment assignment ratios are 1:1 for both A versus  and B versus . We derive in the 
Appendix the actual values of the correlation between U and  under various scenarios. 
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Specifically, for assessing the overall effect of A and the simple effect of AB, the correlation 
is approximately . It then follows from equation (4) that c ≈ 2.1782 for α = 0.05. Thus, 
the overall type I error rate will be 0.05 if we use the nominal significance level of 0.0294 
for each of the two tests. By contrast, the commonly used Bonferroni correction would entail 
the nominal significance level of 0.025, which is > 15% smaller than 0.0294.
Remark 4
Slud (1994) considered the PH model: , where IA and 
IB are indicators for treatments A and B, respectively. He obtained a closed-form expression 
for the covariance matrix of the maximum partial likelihood estimators of (β1, β2, β3) under 
simplifying conditions. Note that β1 and β2 correspond to the simple effects of A and B, 
respectively, while β3 corresponds to the interaction between A and B.
The knowledge of the critical value for each test is very useful when designing a factorial 
study. After the study is completed, we can obtain a more accurate value of c by empirically 
estimating the correlation of U and  from the observed data, although the value of c 
calculated at the design stage is often accurate enough for practical purposes.
3. Simulation Studies
We conducted simulation studies to assess the performance of the proposed methods. We let 
the total sample size n range from 150 to 900 and randomly assigned subjects to A versus 
with a 1:1 or 2:1 ratio and to B versus  with a 1:1 ratio. We generated the survival time T 
from the standard exponential distribution and the censoring time C from the uniform (0, 
1.6) distribution such that the censoring rate is approximately 50%. We focused on the 
estimation of correlation for two sets of comparisons: (1) the overall effect of A and the 
simple effect of AB, and (2) the simple effect of A and the simple effect of AB. We 
investigated the accuracy of the proposed correlation estimators between the two log-rank 
statistics or the two maximum partial likelihood estimators. We considered both the 
unweighted log-rank test and the weighted log-rank test with the Kaplan-Meier estimator as 
the weight function.
We have shown in the Appendix that, under the treatment assignment ratios of 1:1 for A 
versus  and B versus , the correlation between the two log-rank statistics or the two 
maximum partial likelihood estimators for assessing the overall effect of A and the simple 
effect of AB is asymptotically  and the correlation for assessing the simple 
effect of A and the simple effect of AB is asymptotically 1/2. By extending the arguments 
given in the Appendix, we can show that these two correlations are  and 2/3, 
respectively, when the treatment assignment ratio for A versus  is changed to 2:1 while that 
of B versus  remains at 1:1.
The results of the simulation studies are summarized in Table 3. For both the log-rank 
statistics and the maximum partial likelihood estimators, the empirical correlations are close 
to the aforementioned theoretical values. The means of the correlation estimators are slightly 
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below the empirical values for small n but approach the empirical values as n increases. 
Thus, the proposed correlation estimators are accurate enough for practical use.
4. COMBINE Study
Alcohol dependence is a leading preventable cause of morbidity and mortality and a major 
contributor to health care costs (Anton et al., 2006). Most patients with alcohol use disorders 
are never treated in primary care settings and do not receive specialty care. Although 
naltrexone was approved to treat alcoholism, evidence of its efficacy was based on small 
single-site studies using specialist models of treatment. It was of interest whether naltrexone 
is efficacious without specialist intervention and whether its efficacy can be improved by 
adding behavior therapy.
The COMBINE study was designed to assess the efficacy of naltrexone, with or without 
CBI, in treating alcoholism. After baseline assessment and attainment of 4 days of 
abstinence, 1,226 eligible alcohol-dependent individuals were randomly assigned to medical 
management with 16 weeks of naltrexone (100 mg daily) or placebo and were also randomly 
selected to receive CBI. The protocol specified percentage of days abstinent and time to first 
heavy drinking day (≥ 5 standard drinks per day for men, ≥ 4 for women) as two co-primary 
endpoints. Baseline percentage of days abstinent (within 30 days prior to the participant’s 
last drink) and research site were prespecified covariates for both the linear and PH models. 
A Bonferroni-corrected significance level of 0.025 was set a priori to adjust for the two co-
primary endpoints.
It is particularly important to know whether the sole act of taking naltrexone is effective 
given that most problem drinkers are seen in health care settings rather than in specialist 
treatment programs. It is also of interest whether efficacy can be improved by combining 
naltrexone with CBI. To assess the efficacy of naltrexone, we may combine the evidence 
between those who receive CBI and those who do not receive CBI or just focus on the latter 
group. Thus, we consider the overall effect of naltrexone, the simple effect of naltrexone, 
and the simple effect of naltrexone plus CBI.
Table 4 displays the results of the three comparisons. The correlation matrix for the three 
estimates of the log hazard ratios is
To control the overall type I error at the prespecified level of 0.025, the critical value for the 
three tests is approximately 2.573. Thus, the simple effect of naltrexone is significant 
whereas the overall effect of naltrexone and the simple effect of naltrexone plus CBI are not. 
By contrast, the Bonferroni threshold for the three p-values is 0.025/3 ≈ 0.0083, which 
implies that none of the three tests would be significant.
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The Kaplan-Meier curves shown in Figure 1 help to explain the results reported in Table 4. 
The use of naltrexone without CBI has the lowest likelihood of relapse. The combination 
therapy of naltrexone plus CBI is considerably less efficacious than the sole use of 
naltrexone. Thus, the overall effect of naltrexone is less significant than its simple effect. 
The difference between the estimates of the simple and overall effects is 0.161, with an 
estimated standard error of 0.10. The conclusion that the sole act of taking naltrexone is the 
most efficacious intervention has important clinical implications.
5. Discussion
The 2 × 2 factorial design allows one to answer multiple questions about two treatments 
within the same study. If the effects of one treatment are similar among patients who receive 
the other treatment and those who do not, then the 2 × 2 design will be efficient; otherwise, 
the design will reveal the complicated truth (Peto, 1978). In the COMBINE study, the effect 
of the sole use of naltrexone would have been estimated with more precision had we omitted 
CBI from the design. The factorial design, however, provided us with the opportunity to 
answer the question about the efficacy of combination therapy and would have provided 
high power to assess the overall effect of naltrexone had the effects of naltrexone been 
similar among patients who did or did not receive CBI.
Some literature reserves the term “factorial designs” for trials where A is tested against 
placebo stratifying by the level of B and B is tested against placebo stratifying by the level 
of A. We have defined factorial designs by the structure of the design — i.e., subjects 
randomly assigned to all combinations — regardless of the planned inference strategy, 
although we have focused on factorial designs that involve at least one stratified comparison.
Under factorial designs, which comparisons should be subject to type I error correction may 
be uncertain or controversial. In general, the decision depends on particular aspects of a trial, 
such as how scientifically distinct the comparisons are, whether they use the same endpoint, 
whether more than one primary hypothesis relates to the use of a single investigational 
treatment, and how regulatory agencies view the strategy of study sponsors. In the APOLLO 
trial, regulatory input was received indicating that control of the type I error across the 
study’s two primary hypotheses was required.
The 2×2 factorial design can be extended to the 3×3 design if each factor has three levels or 
to the 2 × 2 × 2 design if there are three factors of two levels each. The COMBINE study 
actually employed a 2 × 2 × 2 design to include a second pill, acamprosate (3 g daily), which 
turned out to be totally ineffective. (For the purposes of illustrating a 2 × 2 design, we did 
not consider the use of acamprosate in this paper.) Our general covariance formulas can be 
applied to any factorial design, and the arguments given in the second and third paragraphs 
of the Appendix can be used to obtain the specific expressions for the correlations under 
similar conditions.
For simplicity, we restricted our formulas to time-independent covariates. The proposed 
methods can be extended to time-dependent covariates in a straightforward manner. 
Specifically, we replace Xkj in model (1) and in  by Xkj(t), replace Xkj in L(β) and 
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U(β) and in the first term of Wkj(β) given in (3) by , and replace Xkj in the second 
term of Wkj(β) by .
In some factorial studies, there are multiple primary endpoints. As mentioned in the previous 
section, there were two co-primary endpoints in the COMBINE study. Because we 
approximated the partial likelihood score function by a sum of independent terms, the joint 
distribution of test statistics for any two endpoints follows from the multivariate central limit 
theorem. Had we accounted for the correlation between the two endpoints in the COMBINE 
study, we would have been able to use a less stringent nominal significance level than the 
Bonferroni threshold of 0.025 for each endpoint and thus to make a stronger claim about the 
efficacy of naltrexone.
The main contribution of this work lies in the derivation of the correlation between two 
treatment comparisons with overlapping subjects. The correlation is determined by the 
“influence function” wkj, which is the same ingredient for calculating the covariance matrix 
of the maximum partial likelihood estimators for multivariate failure time data (Wei et al., 
1989). One can obtain Wkj in R, SAS, or STATA and perform the remaining calculations 
according to the formulas provided in Section 2. We have posted on our website (http://
dlin.web.unc.edu/software/) a software program that estimates the correlation between any 
two (possibly stratified) log-rank statistics or two maximum partial likelihood estimators 
under (possibly stratified) PH models from the raw data. The actual values of the 
correlations for various scenarios derived in the Appendix are useful in the design stage and 
may also be accurate enough for the analysis of actual data.
There is some literature on closely related problems. Pocock et al. (1987) derived the 
correlation between the logrank test and a test of proportions in the context of multiple 
endpoints. Follmann et al. (1994) considered group sequential tests for multi-armed clinical 
trials. We can easily extend our work to the group sequential setting because we have 
approximated our statistics by sums of independent terms.
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Appendix: Derivation of Theoretical Results
To derive the theoretical results, we adopt the counting-process martingale formulation. 
Write  and . Define
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It is easy to show that




and ek(β, t) is the limit of . Likewise,  is asymptotically 
equivalent to
(A.3)
where  is analogous to wkj(β). Both (A.1) and (A.3) are sums of independent zero-
mean random vectors. Thus, it follows from the multivariate central limit theorem that the 
joint distribution of U(β) and  is asymptotically multivariate zero-mean normal with 
covariance matrix , where wi(β) and  are, respectively, the values 
of w(β) and  for the the ith subject in the overlapping set.
We now focus on the (weighted) log-rank statistics for testing the null hypotheses H0 : β = 0 
and . It is easy to see that E1(t) ≈ E2(t) for all t under H0 and  provided that the 
treatment does not differentially affect the censoring distribution between the two strata. 
Suppose that the same type of weight function is used for the two strata, such that Q1(t) ≈ 
Q2(t). Thus, we can (approximately) express U as
where , and . Likewise,
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where , and . Suppose that the 
stratification variable does not affect the survival time such that 
 for all t under H0 and . (This is a reasonable 
approximation when designing a trial although it is theoretically possible, for example, for 
treatment B to have a non-zero effect even when treatment A and treatment AB have no 
effect.) Then simple algebraic manipulation yields
and
where
and λ0(·) is the common hazard function.
By the martingale central limit theorem (Andersen and Gill, 1982), U and  are 
asymptotically bivariate zero-mean normal. In addition,
and
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Assume that the treatment assignment ratios are 1:1 for both A versus  and B versus . 
Assume also that the treatments are independent of the survival time and censoring time. 
Then  for all t. We derive below the correlation of U and  under various 
scenarios of interest.
• If U and  pertain to the overall effect of A and the simple effect of A or 
AB, then  and  for i = 1, …, n0. Thus, 
. It follows that 
, which is  since 
.
• If U and  pertain to the overall effects of A and B, then . 
Because Xi and  are independent, we conclude that .
• If U and  pertain to two simple effects, then  and  for i 
= 1, …, n0. Thus, . It follows that 
.
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Kaplan-Meier estimates of the proportion of patients without heaving drinking for the four 
treatment groups in the COMBINE study.
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Table 1
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Table 2

















Placebo for additional antihypertensive drug
(452 patients)






































































































































































































































































































































































































































































































































































































































Lin et al. Page 20
Table 4
Evaluation of Naltrexone With or Without CBI in the COMBINE Study
Treatment Comparison Estimate Std Error Z-Stat p-value
Overall effect of naltrexone −0.085 0.0685 −1.237 0.216
Simple effect of naltrexone −0.252 0.0979 −2.573 0.010
Simple effect of naltrexone + CBI −0.091 0.0955 −0.956 0.339
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